Loading stock data…
Exelixis (EXEL)
$59.01-0.12 (-0.20%)
Pre-Market$59.00-0.01 (-0.02%)· Last close Sep 4
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exelixis, Inc. in the Healthcare sector is trading at $59.01 with a market capitalization of $13.3B. Wall Street consensus targets $53.69 (16 analysts), implying a -9.0% move over the next 12 months. The stock is currently near its 52-week high of $59.72, remaining 23.8% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -9.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $628.69M↑ | $610.81M↑ | $598.66M↑ | $597.75M↑ | $568.26M |
| Gross Profit | $608.03M↑ | $590.86M↑ | $572.18M↓ | $579.18M↑ | $548.79M |
| Operating Income | $248.41M↓ | $251.34M↑ | $235.91M↓ | $256.36M↑ | $213.58M |
| Net Income | $212.05M↑ | $210.47M↓ | $244.53M↑ | $193.58M↑ | $184.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.05%
Volume
Today's trading volume
1.58M
Recent News
ServiceNow Leads Five Stocks To Watch Near Buy Points
Meanwhile, several stocks showed bullish signs, including software giant ServiceNow. Digital bank Dave Inc., commodities trading platform Marex Group, senior living REIT Welltower and cancer treatment developer Exelixis round out the list of stocks to watch in or near buy zones. ServiceNow is in a buy zone after breaking out of a cup base with a buy point of 139.20 on Aug. 28, reclaiming the entry on Sept. 2.
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out
Exelixis is Friday's IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cancer Stock Breaks Out To Highs; Key FDA Action On Watch
Exelixis shares hit an all-time high Wednesday. Exelixis holds third place in IBD's profitable biotech group, according to IBD Stock Checkup. The company has cancer medications approved by the U.S. Food and Drug Administration as well as treatments in its pipeline.
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a